In 102 patients recently hospitalised for HFrEF with CRP of 2 mg/L or more (84 analysed), anakinra for 24 weeks did not improve peak VO2 versus placebo (median change +1.5 vs +1.2 mL/kg/min; P = 0.40); CRP fell 76% vs 48% (P = 0.050).
RCTn = 102
Van Tassell et al. Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra